Rethinking Menopause Hormone Therapy
A JAMA Perspective outlines how updated FDA labeling may reshape menopause care.
-
By
-
Kerri Miller
-
April 23, 2026
-
-
1
Menopausal hormone therapy (MHT) use declined from over 20% to under 5% after the Women’s Health Initiative.
-
2
The FDA's removal of black box warnings on MHT presents an opportunity for improved patient care.
-
3
Research shows that initiating MHT before age 60 or within 10 years of menopause has a favorable benefit-risk profile.
-
4
There are significant gaps in menopause education and symptom screening among clinicians treating middle-aged women.
-
5
The FDA label change emphasizes the need for routine symptom assessment and individualized discussions about MHT.
